By Melissa Lipman ( April 17, 2012, 10:39 PM EDT) -- The U.S. Supreme Court's decision Tuesday allowing Caraco Pharmaceutical Laboratories Ltd. to challenge as overbroad Novo Nordisk A/S's use code for a patent covering diabetes drug Prandin opens the door to an influx of litigation between generics and brand-name drugmakers, but it remains to be seen just how broad the use codes can be, attorneys say....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.